ArticleJournal of clinical microbiology2014
Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Pooled it
- Prevalence of neurocysticercosis and its characteristics among people with epileptic seizures and progressively worsening severe headaches in 60 villages in three provinces of Burkina Faso.PLoS neglected tropical diseases · 2026Trial
- Taenia solium neurocysticercosis: Its current epidemiological, diagnostic, therapeutic, and control landscapes.PLoS neglected tropical diseases · 2026Review
- Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis.Open forum infectious diseases · 2026Article
- Evaluation of a rapid lateral flow assay for the detection of taeniosis and cysticercosis at district hospital level in Tanzania: A prospective multicentre diagnostic accuracy study.PLoS neglected tropical diseases · 2025Article
- Serological diagnosis of cysticercosis in humans and pigs: status, limitations, and prospects.Frontiers in veterinary science · 2025Review
- The performance of a point-of-care test for the diagnosis of Neurocysticercosis in a resource-poor community setting in Zambia - a diagnostic accuracy study.EClinicalMedicine · 2024Article
- Taenia martis Neurocysticercosis-Like Lesion in Child, Associated with Local Source, the Netherlands.Emerging infectious diseases · 2024Article
- From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis.Frontiers in parasitology · 2024Review
- Multiantigen print immunoassay (MAPIA) for the diagnosis of neurocysticercosis: a single-center diagnostic optimization and accuracy study in Lima, Peru.Journal of clinical microbiology · 2023Article
- Characteristics of people with epilepsy and Neurocysticercosis in three eastern African countries-A pooled analysis.PLoS neglected tropical diseases · 2022Article
- Community-level prevalence of epilepsy and of neurocysticercosis among people with epilepsy in the Balaka district of Malawi: A cross-sectional study.PLoS neglected tropical diseases · 2022Article
- Prevalence of Epilepsy, Human Cysticercosis, and Porcine Cysticercosis in Western Kenya.The American journal of tropical medicine and hygiene · 2022Article
- Seroprevalence and Associated Risk Factors of Trichinellosis andTropical medicine and infectious disease · 2022Article
- Prevalence and factors associated with human Taenia solium taeniosis and cysticercosis in twelve remote villages of Ranomafana rainforest, Madagascar.PLoS neglected tropical diseases · 2022Article
- Multiple-bead assay for the differential serodiagnosis of neglected human cestodiases: Neurocysticercosis and cystic echinococcosis.PLoS neglected tropical diseases · 2022Article
- Evaluation of an Antibody Detecting Point of Care Test for Diagnosis ofDiagnostics (Basel, Switzerland) · 2021Article
- Trial Design of a Prospective Multicenter Diagnostic Accuracy Study of a Point-of-Care Test for the Detection ofDiagnostics (Basel, Switzerland) · 2021Article
- Neurocysticercosis. A frequent cause of seizures, epilepsy, and other neurological morbidity in most of the world.Journal of the neurological sciences · 2021Review
- Trial Design for a Diagnostic Accuracy Study of a Point-of-Care Test for the Detection ofDiagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
One of the most well-characterized tests for diagnosing neurocysticercosis (NCC) is the enzyme-linked immunoelectrotransfer blot (EITB) assay developed at the CDC, which uses lentil lectin-bound glycoproteins (LLGP) extracted from Taenia solium cysticerci. Although the test is very reliable, the purification process for the LLGP antigens has been difficult to transfer to other laboratories because of the need for expensive equipment and technical expertise. To develop a simpler assay, we previously purified and cloned the diagnostic glycoproteins in the LLGP fraction. In this study, we evaluated three representative recombinant or synthetic antigens from the LLGP fraction, individually and in different combinations, using an immunoblot assay (recombinant EITB). Using a panel of 249 confirmed NCC-positive and 401 negative blood serum samples, the sensitivity of the recombinant EITB assay was determined to be 99% and the specificity was 99% for diagnosing NCC. We also tested a panel of 239 confirmed NCC-positive serum samples in Lima, Peru, and found similar results. Overall, our data show that the performance characteristics of the recombinant EITB assay are comparable to those of the LLGP-EITB assay. This new recombinant- and synthetic antigen-based assay is sustainable and can be easily transferred to other laboratories in the United States and throughout the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.